585 related articles for article (PubMed ID: 31187526)
1. Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of myeloma therapy: Finding the right path among many standards.
Rajkumar SV
Hematol Oncol; 2021 Jun; 39 Suppl 1():68-72. PubMed ID: 34105809
[No Abstract] [Full Text] [Related]
3. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
4. Emerging options for combination therapy in multiple myeloma.
Rossi AC
Clin Adv Hematol Oncol; 2018 Mar; 16(3):192-194. PubMed ID: 29742074
[No Abstract] [Full Text] [Related]
5. When to recommend a second autograft in patients with relapsed myeloma?
Ziogas DC; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Apr; 58(4):781-787. PubMed ID: 27894207
[TBL] [Abstract][Full Text] [Related]
6. Current Review on High-Risk Multiple Myeloma.
Chan HSH; Chen CI; Reece DE
Curr Hematol Malig Rep; 2017 Apr; 12(2):96-108. PubMed ID: 28317082
[TBL] [Abstract][Full Text] [Related]
7. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
9. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.
Baertsch MA; Lutz R; Raab MS; Weinhold N; Goldschmidt H
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2445-2455. PubMed ID: 31407112
[TBL] [Abstract][Full Text] [Related]
10. How to Think About Risk in Myeloma.
Krishnan A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S135-8. PubMed ID: 27521310
[TBL] [Abstract][Full Text] [Related]
11. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
Cohen AD; Garfall AL; Dogan A; Lacey SF; Martin C; Lendvai N; Vogl DT; Spear M; Lesokhin AM
Blood Adv; 2019 Aug; 3(16):2487-2490. PubMed ID: 31451444
[TBL] [Abstract][Full Text] [Related]
12. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
Muchtar E; Magen H; Gertz MA
Leuk Lymphoma; 2017 Jun; 58(6):1283-1296. PubMed ID: 27734720
[TBL] [Abstract][Full Text] [Related]
13. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Dingli D; Ailawadhi S; Bergsagel PL; Buadi FK; Dispenzieri A; Fonseca R; Gertz MA; Gonsalves WI; Hayman SR; Kapoor P; Kourelis T; Kumar SK; Kyle RA; Lacy MQ; Leung N; Lin Y; Lust JA; Mikhael JR; Reeder CB; Roy V; Russell SJ; Sher T; Stewart AK; Warsame R; Zeldenrust SR; Rajkumar SV; Chanan Khan AA
Mayo Clin Proc; 2017 Apr; 92(4):578-598. PubMed ID: 28291589
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: diagnosis and treatment.
Rajkumar SV; Kyle RA
Mayo Clin Proc; 2005 Oct; 80(10):1371-82. PubMed ID: 16212152
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
16. Advances in understanding prognosis in myeloma.
Smith D; Yong K
Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Lee HC; Raje NS; Landgren O; Upreti VV; Wang J; Avilion AA; Hu X; Rasmussen E; Ngarmchamnanrith G; Fujii H; Spencer A
Leukemia; 2021 Jan; 35(1):255-258. PubMed ID: 32317775
[No Abstract] [Full Text] [Related]
18. Induction Therapy for Newly Diagnosed Multiple Myeloma.
Paul B; Lipe B; Ocio EM; Usmani SZ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e176-e186. PubMed ID: 31099624
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
[TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment of Patients With Relapsed/Refractory Myeloma.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):379-385. PubMed ID: 33714682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
